
What is claimed is:

1. A compound of formula PA3004, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof




PA3004.

2. The compound according to claim 1, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, characterized in that a salt of the compound of formula PA3004 is a pharmaceutically acceptable salt formed from the compound of formula PA3004 with an inorganic acid or an organic acid, or formed from the compound of formula PA3004 with a base, and the compound of formula PA3004 or the salt thereof is amorphous or crystalline.

3. A pharmaceutical composition, comprising a therapeutically effective amount of the compound of claim 1 or 2, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and a pharmaceutically acceptable adjuvant, diluent, or carrier.

4. Use of the compound of claim 1, or an optical isomer, a pharmaceutically acceptable salt, a hydrate or a solvate thereof, in the manufacture of a medicament for treating an acute or chronic disease associated with hepatitis B virus infection.


5. A method for preparing the compound of claim 1, comprising:



(Ia) (I)

(i-b) removing TBS from a compound of formula (Ia) in an inert solvent to form the compound of formula (I),wherein m is 0, R_2 is Cl and R_3 is F;

wherein the compound of formula (Ia) is prepared through the step of:



(Ic) (Ia)

(i-c) subjecting a compound of formula (Ic) and PA3001-3 to a substitution reaction in an inert solvent to obtain the compound of formula (Ia), wherein m is 0, R_2 is Cl and R_3 is F.